Not So FASt: Tumor Cells Resisting Death Drive CAR T-cell Dysfunction

Cancer Discov. 2020 Apr;10(4):492-494. doi: 10.1158/2159-8290.CD-20-0037.

Abstract

In this issue, Singh and colleagues describe a novel tumor-intrinsic mechanism of resistance to chimericantigen receptor (CAR) T-cell therapy targeting CD19 in B-cell malignancies. They show that reduced expression of death receptor genes in the tumors mediates resistance to killing by CAR T cells, leads to progressive CAR T-cell dysfunction, and is associated with unfavorable clinical outcome in patients.See related article by Singh et al., p. 552.

Publication types

  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Antigens, CD19
  • B-Lymphocytes / immunology
  • Humans
  • Leukemia*
  • Receptors, Death Domain
  • T-Lymphocytes* / immunology

Substances

  • Antigens, CD19
  • Receptors, Death Domain